Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.

Patient Prefer Adherence · 2014 · PMC4094627 · PMID 25045252

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The median PFS was superior for VT (39 months) compared with VP (32 months), and OS was also longer in VT patients compared with VP (5-year OS of 69% and 50%, respectively), but the differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.